CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

TXA127Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug2643 Video based exercise Wiki 1.00
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Randomized Controlled Trial of Angiotensin 1-7/ TXA127 for the Treatment of Moderate COVID-19

The purpose of this study is to determine if administration of angiotensin-(1-7) / TXA127 prevents acute kidney injury and deterioration into multi-organ failure in patients with moderate to severe COVID-19

NCT04401423 COVID-19 Drug: TXA127 Drug: Placebo

Primary Outcomes

Description: Defined as an increase of serum creatinine by more than 0.3 mg/dL or 50% above baseline (at enrollment)

Measure: Incidence of acute kidney injury

Time: Day 1 to Day 7

Description: Requiring intubation and ventilatory support

Measure: Incidence of respiratory failure

Time: Day 1 to Day 7

Secondary Outcomes

Description: death

Measure: Mortality

Time: Day 1 to Day 7

Description: Requiring dialysis (either continuous or intermittent)

Measure: Renal failure

Time: Day 1 to Day 7

Description: requiring vasopressors

Measure: Vasoplegic shock

Time: Day 1 to Day 7

Description: measured via blood work

Measure: Inflammatory markers, specifically IL-6 levels

Time: Day 1 to Day 7

Description: defined as a reduction in oxygen requirements from start of experimental drug

Measure: Reduction in supplemental oxygen requirements

Time: Day 1 to Day 7

No related HPO nodes (Using clinical trials)